Pharmaceuticals
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...
2022-11-01 19:40
3526
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
With more than 1,600 employees across the globe, the new organization is now one of the world's largest pharma intelligence solutions providers on the market YARDLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies...
2022-11-01 19:00
5236
Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.
Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. FRANKFURT, Germany, Nov. 1,...
2022-11-01 16:00
4100
Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform
DÜSSELDORF, Germany and PIOMBINO DESE, Italy, Nov. 1, 2022 /PRNewswire/ -- Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics and Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic ...
2022-11-01 15:00
2080
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia ...
2022-11-01 12:12
3833
Codex Genetics to Offer Guardant Health's Precision Oncology Tests in Hong Kong and Macau
HONG KONG, Nov. 1, 2022 /PRNewswire/ -- Codex Genetics today announced an exclusive collaboration with Guardant Health Asia,Middle East and Africa (AMEA) to offer comprehensive genomic profiling (CGP) tests to hospitals and clinics in Hong Kong and Macau. As part of the collaboration, Gua...
2022-11-01 11:21
4839
CBC Healthcare Infrastructure Platform acquires prime industrial land in Shanghai to develop a high-specifications life science park
* 83.76 mu plot within the Life Science zone of the Qingpu Industrial Park, Shanghai Development to include manufacturing facilities and R&D offices SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CBC Healthcare Infrastructure Platform ("CBC HIP"), the infrastructure arm ofAsia's largest healthcare-de...
2022-11-01 11:00
2628
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior V...
2022-10-31 21:30
3656
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
* ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017. * IND clearance enables Antengene to initiate the combination portion of the Phase I "ERASER" clinical trial inthe United States (U.S.) to evalua...
2022-10-31 20:22
3752
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
2022-10-31 19:00
3409
Xinhua Silk Road: Cloud + offline fair injects new vitality into National TCM Materials & Pharmaceuticals Trade Fair
BEIJING, Oct. 31, 2022 /PRNewswire/ -- The 53rd National Traditional Chinese Medicine (TCM) Materials and Pharmaceuticals Trade Fair, a vital platform to promote communication in medical field inChina, bore witness to how online-offline integration greatly boosted trading on the opening day on Fr...
2022-10-31 19:00
5768
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
2505
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, Oct. 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2022-10-31 08:00
4312
Samyang Holdings' Lafullen Makes Splash in Korean Medical Aesthetics Market
- Successfully demonstrated Lafullen's safety and efficacy at autumn medical symposiums - Shared treatment protocols and clinical cases to lecturers by specialist - Continued to develop evidence-based marketing to Asian markets SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Samyang Holdings ...
2022-10-31 08:00
4126
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT
CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...
2022-10-31 05:00
2187
World Stroke Organization Tackle Gaps in Access to Quality Stroke Care
GENEVA, Switzerland, Oct. 28, 2022 /PRNewswire/ -- On World Stroke Day (29th
Oct), the World Stroke Organization has announced the launch of a new program
that aims to drive access to quality acute stroke care and save lives around
the world.
2022-10-29 06:01
10732
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 29, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-29 05:30
10143
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
3820
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2951
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-28 20:30
3198
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
43748
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
33975
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
19123
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
17169
